PL3153171T3 - Samidorfan (alks 33) w połączeniu z buprenorfiną do leczenia zaburzeń depresyjnych - Google Patents

Samidorfan (alks 33) w połączeniu z buprenorfiną do leczenia zaburzeń depresyjnych

Info

Publication number: PL3153171T3
Authority: PL; Poland
Prior art keywords: samidorphan; alks; buprenorphine; treatment; combination
Prior art date: 2011-12-15

Application number

PL16201359T

Other languages

English (en)

Inventor

Daniel Deaver

Elliott EHRICH

Original Assignee

Alkermes Pharma Ireland Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-12-15

Filing date

2012-12-14

Publication date

2019-02-28

2012-12-14 Application filed by Alkermes Pharma Ireland Limited filed Critical Alkermes Pharma Ireland Limited

2019-02-28 Publication of PL3153171T3 publication Critical patent/PL3153171T3/pl

Links

RYIDHLJADOKWFM-MAODMQOUSA-N Samidorphan Chemical compound N1([C@@H]2CC3=CC=C(C(=C3[C@@]3([C@]2(CCC(=O)C3)O)CC1)O)C(=O)N)CC1CC1 RYIDHLJADOKWFM-MAODMQOUSA-N 0.000 title 2
208000020401 Depressive disease Diseases 0.000 title 1
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 title 1
229960001736 buprenorphine Drugs 0.000 title 1
229950006776 samidorphan Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Zoology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL16201359T 2011-12-15 2012-12-14 Samidorfan (alks 33) w połączeniu z buprenorfiną do leczenia zaburzeń depresyjnych PL3153171T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201161576233P	2011-12-15	2011-12-15
EP12830900.2A EP2790702B1 (en)	2011-12-15	2012-12-14	Compositions of buprenorphine and mu-opioid receptor antagonists
EP16201359.3A EP3153171B1 (en)	2011-12-15	2012-12-14	Samidorphan (alks 33) in combination with buprenorphine for the treatment of depressive disorders
PCT/IB2012/002900 WO2013088243A1 (en)	2011-12-15	2012-12-14	Compositions of buprenorphine and mu-opioid receptor antagonists

Publications (1)

Publication Number	Publication Date
PL3153171T3 true PL3153171T3 (pl)	2019-02-28

Family

ID=47757653

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL16201359T PL3153171T3 (pl)	2011-12-15	2012-12-14	Samidorfan (alks 33) w połączeniu z buprenorfiną do leczenia zaburzeń depresyjnych

Country Status (25)

Country	Link
US (8)	US8822488B2 (pl)
EP (3)	EP2790702B1 (pl)
JP (2)	JP6038170B2 (pl)
KR (1)	KR101996108B1 (pl)
CN (2)	CN104159586A (pl)
AU (1)	AU2012351806C1 (pl)
BR (1)	BR112014012409B8 (pl)
CA (1)	CA2858812C (pl)
CY (1)	CY1121081T1 (pl)
DK (1)	DK3153171T3 (pl)
EA (1)	EA030609B8 (pl)
ES (2)	ES2791764T3 (pl)
HR (1)	HRP20181950T1 (pl)
HU (1)	HUE041883T2 (pl)
IL (1)	IL232785B (pl)
LT (1)	LT3153171T (pl)
MX (2)	MX375348B (pl)
PL (1)	PL3153171T3 (pl)
PT (1)	PT3153171T (pl)
RS (1)	RS58322B1 (pl)
SI (1)	SI3153171T1 (pl)
SM (1)	SMT201800664T1 (pl)
TR (1)	TR201815154T4 (pl)
WO (1)	WO2013088243A1 (pl)
ZA (1)	ZA201405029B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2010326676B2 (en)	2009-12-04	2013-03-14	Alkermes Pharma Ireland Limited	Morphinan derivatives for the treatment of drug overdose
PL3446565T3 (pl)	2010-08-23	2024-04-02	Alkermes Pharma Ireland Limited	Sposoby leczenia przyrostu masy ciała wywołanego lekami przeciwpsychotycznymi
PL3153171T3 (pl)	2011-12-15	2019-02-28	Alkermes Pharma Ireland Limited	Samidorfan (alks 33) w połączeniu z buprenorfiną do leczenia zaburzeń depresyjnych
US9211293B2 (en)	2011-12-15	2015-12-15	Alkermes Pharma Ireland Limited	Opioid agonist antagonist combinations
US9656961B2 (en)	2013-05-24	2017-05-23	Alkermes Pharma Ireland Limited	Methods for treating depressive symptoms
WO2014190270A1 (en)	2013-05-24	2014-11-27	Alkermes Pharma Ireland Limited	Morphan and morphinan analogues, and methods of use
WO2016126721A1 (en)	2015-02-02	2016-08-11	Forma Therapeutics, Inc.	3-aryl-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
WO2016126726A1 (en)	2015-02-02	2016-08-11	Forma Therapeutics, Inc.	Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors
EP3472131B1 (en)	2016-06-17	2020-02-19	Forma Therapeutics, Inc.	2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
EP4243768A1 (en)	2020-11-12	2023-09-20	Alkermes Pharma Ireland Limited	Immediate release multilayer tablet

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH581624A5 (pl)	1970-08-14	1976-11-15	Sumitomo Chemical Co
US3856795A (en)	1972-04-25	1974-12-24	American Home Prod	Process for preparation of secondary amines from tertiary amines
US4032529A (en)	1974-09-20	1977-06-28	Sterling Drug Inc.	Aminomethanobenzazocine intermediates
US3957793A (en)	1974-09-20	1976-05-18	Sterling Drug Inc.	Hydroxyiminobenzazocines
US4127577A (en)	1975-11-24	1978-11-28	Sterling Drug Inc.	Aminomethanobenzazocine process
US4205171A (en)	1976-01-12	1980-05-27	Sterling Drug Inc.	Aminomethanobenzazocines and nitromethanobenzazocines
US4464378A (en)	1981-04-28	1984-08-07	University Of Kentucky Research Foundation	Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
GB8332556D0 (en) *	1983-12-06	1984-01-11	Reckitt & Colmann Prod Ltd	Analgesic compositions
US4649200A (en)	1986-05-08	1987-03-10	Regents Of The University Of Minnesota	Substituted pyrroles with opioid receptor activity
US4939264A (en)	1986-07-14	1990-07-03	Abbott Laboratories	Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
US5258386A (en)	1991-06-05	1993-11-02	The United States Of America As Represented By The Secretary Of The Army	(+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents
US5607941A (en)	1992-06-26	1997-03-04	Boehringer Ingelheim Kg	Useful for treating neurodegenerative diseases
SE9103745D0 (sv)	1991-12-18	1991-12-18	Wikstroem Haakan	Aryl-triflates and related compounds
EP0632041A1 (en)	1993-07-01	1995-01-04	Katholieke Universiteit Nijmegen	New morphine derivatives having improved analgesic and narcotic properties
ES2188888T3 (es)	1996-01-10	2003-07-01	Glaxosmithkline Spa	Derivados morfinoides 8ii) con condensados con heterociclos.
GB9709972D0 (en)	1997-05-19	1997-07-09	Pfizer Ltd	Tetrazoles
US7534866B2 (en) *	2005-10-19	2009-05-19	Ibc Pharmaceuticals, Inc.	Methods and compositions for generating bioactive assemblies of increased complexity and uses
GB9912411D0 (en)	1999-05-28	1999-07-28	Pfizer Ltd	Compounds useful in therapy
EP1359146B1 (en)	2000-10-31	2008-04-09	Rensselaer Polytechnic Institute	4-aryl piperidines as opioid receptor binding agents
DK1485051T3 (da) *	2002-03-20	2008-09-08	Euro Celtique Sa	Fremgangsmåde til indgivelse af buprenorphin til behandling af depression
AU2003239389A1 (en)	2002-05-30	2003-12-19	Eli Lilly And Company	Opioid receptor antagonists
ES2485867T3 (es)	2004-05-14	2014-08-14	Janssen Pharmaceutica Nv	Compuestos opioides de carboxamido
US20060063792A1 (en)	2004-09-17	2006-03-23	Adolor Corporation	Substituted morphinans and methods of their use
EP1817291A1 (en)	2004-11-05	2007-08-15	Rensselaer Polytechnic Institute	4-hydroxybenzomorphans
SI1856093T1 (sl)	2005-03-02	2010-03-31	Nycomed Gmbh	Hidrokloridna sol R aR bR dimetoksipiridin il etoksi metoksi a b heksahidrofenantridin ola
ES2423485T3 (es)	2007-03-19	2013-09-20	Acadia Pharmaceuticals Inc.	Asociaciones de agonistas y antagonistas inversos 5-HT2A con antipsicóticos
AU2008286979B2 (en)	2007-08-09	2013-03-28	Rensselaer Polytechnic Institute	Quaternary opioid carboxamides
EP2252150B1 (en) *	2008-02-14	2018-04-11	Alkermes, Inc.	Selective opioid compounds
US8138169B2 (en) *	2008-04-11	2012-03-20	Comgenrx, Inc.	Combination therapy for bipolar disorder
EP2408303A4 (en) *	2009-03-19	2012-07-25	Alkermes Inc	MORPHINANE DERIVATIVES HAVING HIGH ORAL BIOLOGICAL AVAILABILITY
US20120149724A1 (en)	2009-06-04	2012-06-14	The General Hospital Corporation	Modulating endogenous beta-endorphin levels
US8530479B2 (en) *	2009-08-10	2013-09-10	Daljit Singh Dhanoa	Deuterium-enriched alkyl sulfonamides
AU2010326676B2 (en) *	2009-12-04	2013-03-14	Alkermes Pharma Ireland Limited	Morphinan derivatives for the treatment of drug overdose
US9211293B2 (en) *	2011-12-15	2015-12-15	Alkermes Pharma Ireland Limited	Opioid agonist antagonist combinations
PL3153171T3 (pl) *	2011-12-15	2019-02-28	Alkermes Pharma Ireland Limited	Samidorfan (alks 33) w połączeniu z buprenorfiną do leczenia zaburzeń depresyjnych
US9656961B2 (en) *	2013-05-24	2017-05-23	Alkermes Pharma Ireland Limited	Methods for treating depressive symptoms

2012
- 2012-12-14 PL PL16201359T patent/PL3153171T3/pl unknown
- 2012-12-14 JP JP2014546667A patent/JP6038170B2/ja not_active Expired - Fee Related
- 2012-12-14 BR BR112014012409A patent/BR112014012409B8/pt not_active IP Right Cessation
- 2012-12-14 SI SI201231474T patent/SI3153171T1/sl unknown
- 2012-12-14 MX MX2014007042A patent/MX375348B/es active IP Right Grant
- 2012-12-14 RS RS20181543A patent/RS58322B1/sr unknown
- 2012-12-14 EP EP12830900.2A patent/EP2790702B1/en active Active
- 2012-12-14 US US13/715,198 patent/US8822488B2/en active Active
- 2012-12-14 MX MX2020000270A patent/MX391181B/es unknown
- 2012-12-14 ES ES12830900T patent/ES2791764T3/es active Active
- 2012-12-14 AU AU2012351806A patent/AU2012351806C1/en not_active Ceased
- 2012-12-14 KR KR1020147016224A patent/KR101996108B1/ko not_active Expired - Fee Related
- 2012-12-14 CN CN201280062291.6A patent/CN104159586A/zh active Pending
- 2012-12-14 LT LTEP16201359.3T patent/LT3153171T/lt unknown
- 2012-12-14 HU HUE16201359A patent/HUE041883T2/hu unknown
- 2012-12-14 TR TR2018/15154T patent/TR201815154T4/tr unknown
- 2012-12-14 ES ES16201359.3T patent/ES2692771T3/es active Active
- 2012-12-14 WO PCT/IB2012/002900 patent/WO2013088243A1/en not_active Ceased
- 2012-12-14 EP EP16201359.3A patent/EP3153171B1/en active Active
- 2012-12-14 SM SM20180664T patent/SMT201800664T1/it unknown
- 2012-12-14 EP EP18187096.5A patent/EP3415148A1/en not_active Withdrawn
- 2012-12-14 PT PT16201359T patent/PT3153171T/pt unknown
- 2012-12-14 CA CA2858812A patent/CA2858812C/en active Active
- 2012-12-14 EA EA201491153A patent/EA030609B8/ru unknown
- 2012-12-14 CN CN201611052441.1A patent/CN106727562B/zh not_active Expired - Fee Related
- 2012-12-14 DK DK16201359.3T patent/DK3153171T3/en active
2014
- 2014-05-25 IL IL232785A patent/IL232785B/en active IP Right Grant
- 2014-07-10 ZA ZA2014/05029A patent/ZA201405029B/en unknown
- 2014-07-29 US US14/445,407 patent/US9498474B2/en active Active
2016
- 2016-03-10 US US15/066,567 patent/US9918978B2/en not_active Expired - Fee Related
- 2016-07-29 JP JP2016150353A patent/JP6403726B2/ja not_active Expired - Fee Related
- 2016-09-12 US US15/262,628 patent/US9913837B2/en not_active Expired - Fee Related
2017
- 2017-09-28 US US15/718,139 patent/US10314838B2/en active Active
- 2017-10-02 US US15/722,408 patent/US10188643B2/en active Active
2018
- 2018-11-22 HR HRP20181950TT patent/HRP20181950T1/hr unknown
- 2018-12-18 CY CY181101356T patent/CY1121081T1/el unknown
2019
- 2019-04-25 US US16/394,524 patent/US10806731B2/en active Active
2020
- 2020-10-06 US US17/063,892 patent/US20210196703A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL232785A0 (en)	2014-07-31
US10806731B2 (en)	2020-10-20
NZ624056A (en)	2016-07-29
ES2692771T3 (es)	2018-12-05
MX375348B (es)	2025-03-06
HRP20181950T1 (hr)	2019-03-22
US20160256450A1 (en)	2016-09-08
US20170056392A1 (en)	2017-03-02
CN106727562B (zh)	2019-07-05
IL232785B (en)	2021-04-29
SI3153171T1 (sl)	2019-01-31
US9913837B2 (en)	2018-03-13
HUE041883T2 (hu)	2019-06-28
WO2013088243A1 (en)	2013-06-20
BR112014012409B1 (pt)	2022-08-23
KR20140107258A (ko)	2014-09-04
MX391181B (es)	2025-03-21
ES2791764T3 (es)	2020-11-05
TR201815154T4 (tr)	2018-11-21
LT3153171T (lt)	2018-12-10
US20180078543A1 (en)	2018-03-22
US9498474B2 (en)	2016-11-22
AU2012351806C1 (en)	2016-06-16
MX2014007042A (es)	2015-01-22
PT3153171T (pt)	2018-11-16
RS58322B1 (sr)	2019-03-29
BR112014012409A2 (pt)	2017-06-13
US20210196703A1 (en)	2021-07-01
EA201491153A1 (ru)	2015-04-30
EA030609B1 (ru)	2018-08-31
KR101996108B1 (ko)	2019-10-01
US20130190342A1 (en)	2013-07-25
CN104159586A (zh)	2014-11-19
CA2858812C (en)	2019-02-26
CA2858812A1 (en)	2013-06-20
JP2015505853A (ja)	2015-02-26
DK3153171T3 (en)	2018-11-19
CN106727562A (zh)	2017-05-31
EA030609B8 (ru)	2018-10-31
US10188643B2 (en)	2019-01-29
JP2016222706A (ja)	2016-12-28
US20180078542A1 (en)	2018-03-22
EP2790702A1 (en)	2014-10-22
JP6403726B2 (ja)	2018-10-10
EP3153171A1 (en)	2017-04-12
EP2790702B1 (en)	2020-04-01
AU2012351806B2 (en)	2016-03-10
BR112014012409B8 (pt)	2022-09-13
US8822488B2 (en)	2014-09-02
US20150051240A1 (en)	2015-02-19
ZA201405029B (en)	2015-10-28
EP3415148A1 (en)	2018-12-19
US10314838B2 (en)	2019-06-11
CY1121081T1 (el)	2019-12-11
JP6038170B2 (ja)	2016-12-07
US9918978B2 (en)	2018-03-20
US20190247387A1 (en)	2019-08-15
EP3153171B1 (en)	2018-09-19
AU2012351806A1 (en)	2014-05-15
SMT201800664T1 (it)	2019-01-11

Publication	Publication Date	Title
HRP20181950T1 (hr)	2019-03-22	Samidorfan (alks 33) u kombinaciji s buprenorfinom za liječenje depresivnih poremećaja
IL229257A0 (en)	2014-01-30	Preparations and methods for the treatment of diseases related to the retina of the eye
EP2552433A4 (en)	2013-11-06	COMPOSITIONS AND METHODS OF TREATING SOMATOSENSORY DISEASES
GB201115711D0 (en)	2011-10-26	Phyto-cannabinoids for use in the treatment of cancer
IL226401A0 (en)	2013-07-31	Methods for treating disorders related to @fgfBA
ZA201307793B (en)	2015-04-29	Novel compound useful for the treatment of degenerative and inflammatory diseases
EP2621499A4 (en)	2014-04-09	METHODS OF TREATING ALLERGIC DISEASES
AP2014007533A0 (en)	2014-03-31	Substituted benzylindazoles for use as BUB1 kinaseinhibitors in the treatment of hyperproliferative diseases
ZA201304334B (en)	2014-12-23	Methods for diagnosing and treating eye-length related disorders
SG2014014724A (en)	2014-07-30	METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
IL228541A0 (en)	2013-12-31	Compounds for the treatment of neurological disorders
ZA201304822B (en)	2014-03-26	Azetidine derivatives useful for the treatment of metabolic and inflimmatory diseases
SG11201401202YA (en)	2014-06-27	Antagonists of il17c for the treatment of inflammatory disorders
PL2726470T3 (pl)	2015-09-30	Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych
GB2496688B (en)	2016-06-29	Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
IL231593B (en)	2019-01-31	Buprenorphine for the treatment of acute suicidality
EP2709632A4 (en)	2015-03-04	COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES
PT2691103T (pt)	2016-10-25	Método para o tratamento de distúrbios da pele
ZA201408060B (en)	2016-03-30	Compositions and methods for the treatment of neurological disorders
ZA201408061B (en)	2016-04-28	Compositions and methods for the treatment of neurological disorders
ZA201408058B (en)	2016-03-30	Compositions and methods for the treatment of epilepsy
PH12014501052A1 (en)	2014-06-30	Methods and compositions for the treatment of diabetes and related symptoms
ZA201308176B (en)	2015-12-23	Therapeutic treatment
EP2531186A4 (en)	2013-07-17	TREATMENT OF HAIR DRESSES
GB201009037D0 (en)	2010-07-14	Compositions and methods for treating disorders associated with atherosclerotic plaques